Slovakia Pharmaceuticals and Healthcare Report Q1 2010

Executive Summary ..................................5
SWOT Analysis..........................................6
Slovakia Pharmaceuticals Industry SWOT ..................................................... 6
Slovakia Political SWOT.............................. 7
Slovakia Economic SWOT ........................... 7
Slovakia Business Environment SWOT ........ 8
Pharmaceutical Business Environment Ratings .......................................9
Table: Regional Pharmaceutical Business Environment Ratings Q110........... 9
Limits Of Potential Returns........................ 10
Risks To Realisation Of Returns ................ 10
Slovakia – Market Summary...................12
Regulatory Regime..................................13
Generic Drug Legislation .......................... 13
Intellectual Property Regime ..................... 14
IP Deficiencies........................................... 15
Pricing Regime .......................................... 16
Reimbursement Regime.............................. 18
Pricing Developments................................ 18
Eurozone Entry .......................................... 19
Table: Slovakia – Exchange Rates, 2005-2013............................................. 20
Industry Trends And Developments ......21
Epidemiology............................................. 21
Table: Main Causes Of Mortality And Morbidity In Slovakia, 2006.............. 21
Table: Disease Burden In CEE.................. 23
Healthcare Sector ...................................... 24
Healthcare Sector Reforms ........................ 25
Health Insurance ....................................... 25
Recent Health Insurance Developments........................................................ 28
Healthcare Funding Crisis ........................ 30
Regional Healthcare Sector Developments................................................... 30
Research And Development ....................... 32
Industry Forecast Scenario .....................33
Overall Market Forecast............................ 33
Key Growth Factors – Industry.................. 34
Key Growth Factors – Macroeconomic ........................................................ 35
Table: Slovakia – Economic Activity, 2007-2014......................................... 37
Prescription Market Forecast .................... 38
Patented Drug Market Forecast ................ 39
Generic Drug Market Forecast.................. 40
OTC Medicine Market Forecast ................ 41
Export/Import Forecasts............................ 42
Medical Device Market Forecast............... 43
Table: EU Medical Device Classifications ................................................... 43
Other Healthcare Data Forecasts.............. 45
Key Risks To BMI’s Forecast Scenario...... 45
Competitive Landscape..........................47
Pharmaceutical Industry............................ 47
Recent Pharmaceutical Industry Developments............................................ 47
Distribution Sector..................................... 48
Company Monitor....................................50
Multinational Company Profiles..................... 50
GlaxoSmithKline (GSK)............................. 50
Sanofi-Aventis............................................ 51
Pfizer ......................................................... 53
Indigenous Company Profiles......................... 54
Zentiva (now merged with Sanofi-Aventis and incorporating Sicomed)......... 54
Biotika ....................................................... 57
Hoechst-Biotika (to be renamed HBM Pharma Ltd)..................................... 58
Imuna Pharma ........................................... 59
Country Snapshot: Slovakia Demographic Data .....................................60
Section 1: Population: ............................... 60
Table: Demographic Indicators................. 60
Table: Rural/Urban Breakdown ................ 61
Section 2: Education & Healthcare ........... 61
Table: Education ....................................... 61
Table: Healthcare: Vital Statistics............. 61
Section 3: Labour Market And Spending Power ........................................... 62
Table: Employment Indicators................... 62
Table: Consumption And Stratification...... 62
Table: Wages Per Year .............................. 63
BMI Methodology ....................................64
How We Generate Our Pharmaceutical Industry Forecasts .............................. 64
Pharmaceutical Business Environment Ratings Methodology ........................... 65
Ratings Overview....................................... 65
Table: Pharmaceutical Business Environment Indicators ............................ 66
Weighting................................................... 67
Table: Weighting Of Components.............. 67
Sources ........ 67
Data Tables ..............................................68